"After a limited market release for NovoSorb MTX, we have started rolling product out across US, New Zealand, and Hong Kong. The appetite from our customer base is strong, with our US team reaching an impressive milestone of US $ 1 M in product sales. We are looking forward to launching multiple variants of NovoSorb MTX, including a particulate variant which has generated a lot of interest among clinicians for soft tissue reconstruction in difficult to access and undulating wounds.
Our R&D and clinical teams have worked with clinicians across the world to understand various soft tissue reconstruction pain points. With their help and a partnership with universities in U.S. and Australia, we are testing and refining a new product portfolio in burns, trauma as well as implantable products for hernia and other Plastic reconstructive procedures. We are grateful to the Victorian Government for a A$2 M grant, part sponsorship funding for R&D lab expansion and new equipment purchase, subject to us meeting agreed milestones. With consistent rollout of new products over next three-year horizon, we are looking to expand our global reach and patient impact. "
"The momentum for geographic expansion continues with registrations obtained for Thailand, Peru, Bolivia, Ecuador, Nepal, Sri Lanka, and Bangladesh. Additionally, we have signed the commercial partner for Japan launch with an initial meeting with regulatory body scheduled in November 2024."
PNV Price at posting:
$2.16 Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)